Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06512194 · ClinicalTrials.gov registry record · Phase 2
Investigation to Understand and Optimize Psilocybin
A Phase 2 study of Depression, sponsored by Charles Raison.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
- 1
- Study location
NCT06512194: Recruiting Phase 2 study of Depression, sponsored by Charles Raison.
NCT06512194 is a Phase 2 study of Depression that is actively recruiting participants, run by Charles Raison. The registered enrollment target is 141 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06512194, a Phase 2 study of Depression, is actively recruiting participants, sponsored by Charles Raison.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression. It will also assess whether different post-dosing interventions, including a non-invasive technique called transcutaneous auricular Vagus Nerve Stimulation (taVNS), influence various psychological and behavioral outcomes. In addition, the study will explore objective measures of real-world social behavior and identify early behavioral responses that may be associated with long-term treatment outcomes.
Primary Outcome
The MADRS is a 10-item depression rating scale that includes questions on the following symptoms: 1. Reported sadness, 2. Apparent sadness, 3. Inner tension, 4. Reduced sleep, 5. Reduced appetite, 6. Concentration difficulties, 7. Lassitude, 8. Inability to feel, 9. Pessimistic thoughts, and 10. Suicidal thoughts. Items are scored via a blinded clinical interview and rated to capture the patient's clinical state over the prior week. Each item yields a score of 0 to 6, and higher scores indicate
Conditions Studied
Interventions
- DRUG Psilocybin
- DEVICE Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
- DEVICE Sham taVNS
Study Locations (1)
Colorado
- Vail Health Behavioral Health - Edwards
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2029-05 |
| Phase | Phase 2 |
What NCT06512194 shows while recruiting
NCT06512194 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 3 interventions - of which Psilocybin is the first listed.
NCT06512194 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06512194 about?
NCT06512194 is a clinical study titled "Investigation to Understand and Optimize Psilocybin". This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression. It will also assess whether different post-dosing interventions, including a non-invasive technique called transcutaneous auricular Vagus Nerve Stimulation (taVNS),...
What is the current status of trial NCT06512194?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2025-05-13. Estimated completion is 2029-05.
What conditions does trial NCT06512194 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT06512194?
The interventions under investigation include: Psilocybin (DRUG), Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) (DEVICE), Sham taVNS (DEVICE).
Who is sponsoring clinical trial NCT06512194?
This trial is sponsored by Charles Raison, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06512194 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06512194's enrollment target sits among peer trials
141 270th of 679 higher than 409 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy